Back to News & Events

SBU & CFB Receive Empire State Development Life Science Entrepreneur Development Award

Stony Brook University, College of Business in partnership with the Center for Biotechnology and Department of Biomedical Engineering has been awarded an Empire State Development Life Science Entrepreneur Development grant to address the growing need for entrepreneurial talent in New York’s life science ecosystem. These entrepreneur development grants will help close the talent gap that has previously limited life science commercialization in the state and will develop entrepreneurs with the mix of skills and expertise needed to successfully guide innovative life science startups along the path to commercial viability.

Five graduate schools of business working in collaboration with graduate programs in the life sciences have been awarded grants of up to $500,000 each to implement a new MBA concentration or certificate in life science entrepreneurship. Collaborations between the business school and life science graduate program are critical to equipping students with the skills needed to become leaders in New York’s growing life science ecosystem.

Dr. Clinton Rubin, Director of the Center for Biotechnology commented, “We hope to build from this NYS entrepreneurship education program to train the next generation of bioscience industry leaders. these students are perfectly placed to help lift NYS biotech to the next level, and translate next generation therapeutics, diagnostics and medical devices from the academic to the business sector.”

Read the full Empire State Development press release here.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 5065
                    [post_author] => 4
                    [post_date] => 2026-09-01 14:03:32
                    [post_date_gmt] => 2026-09-01 18:03:32
                    [post_content] => 

Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.

BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.

Application deadline: October 29, 2026, 5:00pm ET

For info sessions, eligibility and deadlines visit our REACH Website and FAQ.

The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.

Questions? Reach out to our program contacts or sign up for office hours:

Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here

Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here

[post_title] => BioREACH: Translational Research Funding Opportunity [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bioreach-translational-research-funding-opportunity [to_ping] => [pinged] => [post_modified] => 2026-09-04 11:55:36 [post_modified_gmt] => 2026-09-04 15:55:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5065 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3912 [post_author] => 3 [post_date] => 2022-08-22 13:06:25 [post_date_gmt] => 2022-08-22 13:06:25 [post_content] =>

November 2-3, 2022 | Virtual

The Life Sciences Summit is an exclusive early stage investor and business development conference that highlights innovation. The objective of the event is to provide an intimate setting allowing emerging biotech companies and academic innovators to connect with the capital and strategic partners they will need to move new discoveries through clinical development.

The virtual 2022 program features thought provoking plenary sessions, presentations by promising young companies with transformative science, the "innovation pipeline" featuring academic innovators and pre-seed stage companies working on cutting edge technologies, and 1:1 networking opportunities.

View full details onlifesciencessummit.org

[post_title] => Save the Date! LSS 2022 [post_excerpt] => Join the Center for Biotechnology November 2-3 at our Virtual Life Sciences Summit 2022! [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => save-the-date-lss-2022 [to_ping] => [pinged] => [post_modified] => 2022-12-13 17:04:15 [post_modified_gmt] => 2022-12-13 17:04:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3912 [menu_order] => 23 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 4445 [post_author] => 4 [post_date] => 2024-06-10 15:37:44 [post_date_gmt] => 2024-06-10 19:37:44 [post_content] =>

Envisagenics, an AI-enabled biotechnology firm specializing in RNA splicing therapeutics, has announced the completion of its Series B funding round. This round included investments from existing supporters Third Kind Venture Capital, Empire State Development, and Red Cell Partners, as well as new strategic investor Bristol Myers Squibb, which has been collaborating with Envisagenics on oncology research since 2022.

Read more about Envisagenics Series B award here.

[post_title] => CFB Client Envisagenics Secures $25 Million Series B Funding to Advance RNA Splicing Therapeutics [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => envisagenics-secures-25-million-series-b-funding-to-advance-rna-splicing-therapeutics [to_ping] => [pinged] => [post_modified] => 2025-05-01 12:39:53 [post_modified_gmt] => 2025-05-01 16:39:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4445 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2939 [post_author] => 3 [post_date] => 2018-02-01 16:55:18 [post_date_gmt] => 2018-02-01 16:55:18 [post_content] =>

Chronus Pharmaceuticals has announced that it has received a $299,172 Phase I Small Business Technology Transfer (STTR) award in partnership with the Department of Chemistry at Stony Brook University.

Funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) will be used to establish feasibility of an antibody diagnostic for detecting childhood tuberculosis. The research will be lead by LIBH Researcher Nicole S. Sampson, PhD in the Department of Chemistry, who will serve as principle investigator on the award and work in close collaboration with Chronus Pharmaceuticals. [post_title] => Chronus Pharmaceuticals Receives Phase I STTR [post_excerpt] => Chronus Pharmaceuticals has received a $299,172 Phase I Small Business Technology Transfer (STTR) award in partnership with the Department of Chemistry at Stony Brook University. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => chronus-pharmaceuticals-receives-phase-i-sttr [to_ping] => [pinged] => [post_modified] => 2018-02-01 16:55:18 [post_modified_gmt] => 2018-02-01 16:55:18 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2939 [menu_order] => 125 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 5065 [post_author] => 4 [post_date] => 2026-09-01 14:03:32 [post_date_gmt] => 2026-09-01 18:03:32 [post_content] =>

Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.

BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.

Application deadline: October 29, 2026, 5:00pm ET

For info sessions, eligibility and deadlines visit our REACH Website and FAQ.

The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.

Questions? Reach out to our program contacts or sign up for office hours:

Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here

Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here

[post_title] => BioREACH: Translational Research Funding Opportunity [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bioreach-translational-research-funding-opportunity [to_ping] => [pinged] => [post_modified] => 2026-09-04 11:55:36 [post_modified_gmt] => 2026-09-04 15:55:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5065 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 288 [max_num_pages] => 96 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

BioREACH: Translational Research Funding Opportunity

More Information

Save the Date! LSS 2022

More Information

CFB Client Envisagenics Secures $25 Million Series B Funding to Advance RNA Splicing Therapeutics

More Information

Chronus Pharmaceuticals Receives Phase I STTR

More Information